Trial Profile
A trial to compare the outcome of octogenarian versus (vs) young patients (pts) with metastatic renal cell carcinoma (mRCC), treated with sunitinib (su)
Status:
Not stated
Phase of Trial:
Phase IV
Latest Information Update: 08 Aug 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 08 Aug 2016 New trial record